A Phase 3 interventional study of Anecortave Acetate Sterile Suspension, 30 mg/mL and Anecortave Acetate Sterile Suspension, 60 mg/ML in AMD, sponsored by Alcon Research. Terminated at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-11-28.
Sponsored by Alcon Research · Phase 3, Interventional, and Prevention
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.
Alcon Research is the lead sponsor of 608 studies on the registry; 9 are open to participants now.
Of its 109 completed or terminated interventional studies of FDA-regulated products, 99 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL
Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
Drug: Anecortave Acetate Sterile Suspension, 60 mg/ML
Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
Other: Anecortave Acetate Vehicle
Posterior juxtascleral administration of suspension
Posterior juxtascleral administration of suspension
Sham posterior juxtascleral administration of suspension
Proportion of patients with sight-threatening CNV in study eye
Time frame: Month 48
Time to development of sight-threatening CNV
Time frame: Up to 48 months
Proportion of patients with stable vision
Time frame: Up to 48 months
This study is terminated, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alcon Research